What's the difference between Wegovy and Ozempic?

Same molecule (semaglutide), different label. Wegovy is FDA-approved for chronic weight management at a higher dose (2.4 mg weekly). Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Same manufacturer (Novo Nordisk), separate supply chains, separate insurance benefits.

Are GLP-1s safe for long-term use?

Trials have followed patients for 2+ years on continuous treatment. The safety profile is consistent with what was seen in shorter studies — GI side effects most common, rare serious events (pancreatitis, gallbladder disease). The boxed warning for thyroid C-cell tumors is based on rodent data; human relevance is unclear. Long-term cardiovascular outcomes have been favorable (SELECT, SUSTAIN-6).

Why are GLP-1s so expensive?

Branded GLP-1s are protected by patents until the late 2020s. List prices ($1,000-1,350/month) reflect what manufacturers negotiate with pharmacy benefit managers. Real-world cash-pay floors are lower: NovoCare $499, LillyDirect $349-549, orforglipron $149.

Do GLP-1s work without diet and exercise?

Trials combine medication with lifestyle counseling — that's the on-label use. Real-world data shows medication carries most of the weight-loss effect, but maintenance after stopping (which the data shows is often poor) depends heavily on the lifestyle layer built during treatment.

GLP-1 receptor agonists

Target: Glucagon-like peptide-1 receptor

Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.

Content current as of June 2026; updated when guidance or availability changes.

Last verified June 1, 2026by glpzoom Editorial Team against primary sources

0-22%: mean weight loss in trials
Weekly: standard injection cadence
~0%: STEP-1 trial discontinuation rate
$0-499/mo: 2026 cash-pay floor

What are glp-1 receptor agonists?

GLP-1 receptor agonists are a class of injectable and oral medications that mimic the incretin hormone GLP-1. Originally developed for type 2 diabetes, the class has become the dominant pharmacologic treatment for chronic weight management following FDA approvals of semaglutide (2021) and tirzepatide (2023) for obesity.

How do glp-1 receptor agonists work?

These molecules bind the GLP-1 receptor (and in tirzepatide's case, the GIP receptor as well), triggering glucose-dependent insulin secretion, suppression of glucagon, delayed gastric emptying, and central appetite suppression. The net effect is improved glycemic control plus 10-22% body-weight reduction in trial populations, sustained as long as therapy continues.

History of glp-1 receptor agonists

Exenatide (Byetta, 2005) was the first commercial GLP-1 agonist, derived from Gila monster saliva. Liraglutide (Victoza/Saxenda, 2010/2014) extended dosing to once-daily. Semaglutide (Ozempic/Wegovy, 2017/2021) and tirzepatide (Mounjaro/Zepbound, 2022/2023) brought once-weekly dosing and the modern weight-loss indication. Oral semaglutide (Rybelsus, 2019) opened oral delivery. The class is now Novo Nordisk and Eli Lilly's flagship franchise.

Efficacy across this class

Mean weight-loss / efficacy reported in pivotal trial

Wegovy
14.9%
Zepbound
20.9%
Ozempic
1.8%
Mounjaro
2.3%
Saxenda
8.4%

Editorial estimate from each drug's primary pivotal trial. Trial design, duration, and patient population vary — direct head-to-head comparisons would require parallel-arm RCTs that mostly don't exist.

Drugs in this class

Other drug classes

PDE5 inhibitors

Phosphodiesterase type 5 (PDE5) inhibitors are the first-line oral treatment for erectile dysfunction. They work by blocking PDE5 from break

hair loss

5-alpha reductase inhibitors

5-alpha reductase inhibitors slow the conversion of testosterone to dihydrotestosterone (DHT), the androgen primarily responsible for male-p

skincare

Topical retinoids

Topical retinoids are vitamin A derivatives applied to the skin to accelerate cell turnover, reduce comedonal acne, and reverse photodamage.

Sources

Primary sources cited above. FDA labeling, peer-reviewed trials, and specialty-society guidelines only.

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) · New England Journal of Medicine, 2021 · PMID 33567185
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine, 2022 · PMID 35658024
Semaglutide and Cardiovascular Outcomes in Obesity (SELECT) · New England Journal of Medicine, 2023 · PMID 37952131